These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7583688)

  • 1. Serial studies of free radical and antioxidant activity in motor neurone disease and the effect of selegiline.
    Mitchell JD; Houghton E; Rostron G; Wignall C; Gatt JA; Phillips TM; Kilshaw J; Shaw IC
    Neurodegeneration; 1995 Jun; 4(2):233-5. PubMed ID: 7583688
    [No Abstract]   [Full Text] [Related]  

  • 2. Free-radical toxicity and antioxidant medications in Parkinson's disease.
    Ciccone CD
    Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
    [No Abstract]   [Full Text] [Related]  

  • 3. Cu/Zn superoxide dismutase free radicals, and motoneuron disease.
    Mitchell JD; Gatt JA; Phillips TM; Houghton E; Rostron G; Wignall C; Whittington J; Shaw IC
    Lancet; 1993 Oct; 342(8878):1051-2. PubMed ID: 8105281
    [No Abstract]   [Full Text] [Related]  

  • 4. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
    Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
    Olanow CW
    J Neural Transm Suppl; 1996; 48():75-84. PubMed ID: 8988463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole: a glimmer of hope in the treatment of motor neurone disease.
    Kiernan MC
    Med J Aust; 2005 Apr; 182(7):319-20. PubMed ID: 15804220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of a novel free radical scavenger, OPC-14117, on wobbler mouse motor neuron disease.
    Abe K; Morita S; Kikuchi T; Itoyama Y
    J Neurosci Res; 1997 Apr; 48(1):63-70. PubMed ID: 9086182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats.
    Carageorgiou H; Zarros A; Tsakiris S
    Pharmacol Res; 2003 Sep; 48(3):245-51. PubMed ID: 12860442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons.
    Sharma SK; Carlson EC; Ebadi M
    J Neurocytol; 2003 May; 32(4):329-43. PubMed ID: 14724376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can nimodipine affect progression of motor neuron disease? A double-blind pilot study.
    Ziv I; Achiron A; Djaldetti R; Abraham M; Melamed E
    Clin Neuropharmacol; 1994 Oct; 17(5):423-8. PubMed ID: 9316691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy.
    Kitani K; Minami C; Yamamoto T; Maruyama W; Kanai S; Ivy GO; Carrillo MC
    Ann N Y Acad Sci; 2001 Apr; 928():248-60. PubMed ID: 11795516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Easier access to motor neurone drug.
    Smith W
    Nurs N Z; 2004 Oct; 10(9):5. PubMed ID: 19777649
    [No Abstract]   [Full Text] [Related]  

  • 14. Riluzole for motor neurone disease. More trials are needed.
    Sandercock J; Burls A; Hyde C; Fry-Smith A; Barton P; Bryan S; Stewart A
    BMJ; 2001 May; 322(7297):1305. PubMed ID: 11403060
    [No Abstract]   [Full Text] [Related]  

  • 15. Riluzole for motor neurone disease. Reply from chairman of appraisal committee at NICE.
    Barnett D
    BMJ; 2001 Sep; 323(7312):573. PubMed ID: 11573490
    [No Abstract]   [Full Text] [Related]  

  • 16. Trophic effects of selegiline on cultured dopaminergic neurons.
    Kontkanen O; Castrén E
    Brain Res; 1999 May; 829(1-2):190-2. PubMed ID: 10350547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riluzole: a glimmer of hope in the treatment of motor neurone disease.
    Henderson RD; McCombe PA
    Med J Aust; 2005 Aug; 183(3):164; author reply 164-5. PubMed ID: 16053424
    [No Abstract]   [Full Text] [Related]  

  • 18. Selegiline stimulates biosynthesis of cytokines interleukin-1 beta and interleukin-6.
    Wilfried K; Müller T; Krüger R; Horst P
    Neuroreport; 1996 Nov; 7(18):2847-8. PubMed ID: 9116194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection by selegiline and other MAO inhibitors.
    Stern G
    J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole for motor neurone disease. Large, more economical trial is needed.
    Wheatley K; Gray R
    BMJ; 2001 May; 322(7297):1305. PubMed ID: 11403061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.